Asset Details
Do you wish to reserve the book?
Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug response
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug response
Do you wish to request the book?
Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug response
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug response
2024
Overview
Breast cancer (BCa) is a major global health challenge. The BCa genome often carries extensive somatic copy number alterations (CNAs), including gains/amplifications and losses/deletions. These CNAs significantly affect tumor development, drug response and patient survival. However, how individual CNAs contribute is mostly elusive. We identified loss of chromosome 13q14.2 as a key CNA in BCa, occurring in up to 63% of patients, depending on the subtype, and correlating with poor survival. Through multi-omics and in vitro analyses, we uncover a paradoxical role of 13q14.2 loss, promoting both cell cycle and pro-apoptotic pathways in cancer cells, while also associating with increased NK cell and macrophage populations in the tumor microenvironment. Notably, 13q14.2 loss increases BCa susceptibility to BCL2 inhibitors, both in vitro and in patient-derived xenografts. Thus, 13q14.2 loss could serve as a biomarker for BCa prognosis and treatment, potentially improving outcomes for BCa patients.
Graphical abstract
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Antineoplastic Agents - pharmacology
/ Antineoplastic Agents - therapeutic use
/ Biomarkers, Tumor - genetics
/ Biomedical and Life Sciences
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - pathology
/ Cancer
/ Chromosomes, Human, Pair 13 - genetics
/ Datasets
/ Female
/ Gene Expression Regulation, Neoplastic
/ Genomes
/ Genomics
/ Humans
/ Killer Cells, Natural - immunology
/ Killer Cells, Natural - metabolism
/ Mice
/ Mutation
/ Oncology
/ Patients
/ Proteins
/ Proto-Oncogene Proteins c-bcl-2 - genetics
/ Proto-Oncogene Proteins c-bcl-2 - metabolism
/ Tumor Microenvironment - genetics
/ Tumors
